Clinical Collaboration for Bayer, Bristol Myers Squibb and Ono to evaluate Stivarga Opdivo Combo

A clinical collaboration has occurred between Bayer, Bristol Myers Squib band Ono Pharmaceutical to evaluate the combination of Stivarga with Opdivo in patients with stable metastatic colorectal (Bowel) cancer (MSS, mCRC).
Stivarga has demonstrated an overall survival benefit on its own, but encouraging data has been seen when combined with Opdivo, showing promising results (phase Ib Regonivo). This detail dates was presented at the Annual American Society of Clinical Oncology meeting earlier this year.
Bowel cancer is one of the most common types of cancer to be diagnosed in the UK, with most patients being over the age of 60. Scott Z Fields, senior vice president and head of Oncology Development at Bayer’s Pharmaceuticals Division commented on the findings “the data shown in the Regonivo, warrants further exploring, and we’re excited to enter into a clinical collaboration to evaluate this. We hope to deliver an additional benefit to patients.”